• Tunable Human Intestinal Organoids: Balancing Renewal and Di

  2026-07-13

  This study presents a tunable human intestinal organoid system that achieves a controlled balance between stem cell self-renewal and differentiation by combining specific small molecule pathway modulators, including GSK-3 inhibitors. The approach enables scalable, diverse organoid cultures, advancing applications in disease modeling and high-throughput research.

• Fosinopril Sodium: Clinical Pharmacokinetics and Research Im

  2026-07-13

  This article analyzes the seminal review on fosinopril sodium, a third-generation ACE inhibitor, highlighting its unique phosphinic acid structure, dual renal-hepatic elimination, and clinical pharmacokinetics. The findings inform improved hypertension research protocols and model design, particularly in populations with renal impairment.

• Romidepsin (FK228) for Cancer Epigenetics: Protocols & Insig

  2026-07-12

  Romidepsin (FK228) is a class I-selective HDAC inhibitor that enables precise epigenetic modulation and robust apoptosis induction in translational cancer research. This article delivers workflow-ready protocols, troubleshooting guidance, and integrative perspectives from recent multidimensional proteomics, empowering researchers to advance cancer biology with confidence.

• C8-HSL Drives Lung Cancer Progression via PI3K/AKT/ERK Activ

  2026-07-10

  The referenced study uncovers that the bacterial quorum-sensing molecule N-octanoyl-L-Homoserine lactone (C8-HSL) directly promotes lung cancer cell proliferation, migration, and invasion through activation of the PI3K/AKT/ERK pathway. These mechanistic insights establish a novel link between microbial communication signals and cancer aggressiveness, suggesting new directions for microbial pathogenicity research and potential therapeutic monitoring.

• Light-Inducible RNA Switches for Precision Gene Therapy Cont

  2026-07-09

  This study presents a rationally engineered light-inducible RNA-releasing protein (LIRP) that enables precise, reversible control of therapeutic gene expression in vivo. The approach demonstrates flexible optogenetic regulation in metabolic and retinal disease models, offering new options for safety and spatiotemporal precision in gene and cell therapy.

• Telmisartan (SKU A8531): Enhancing Cardiac Hypertrophy Resea

  2026-07-09

  This article explores scenario-driven laboratory challenges in cardiovascular disease research, focusing on how Telmisartan (SKU A8531) serves as a reliable angiotensin II receptor antagonist. Through evidence-based Q&A, we illustrate practical solutions for assay reproducibility, data interpretation, and workflow optimization, underscoring Telmisartan's validated performance and compatibility.

• 3-Deazaadenosine Hydrochloride: Precision SAHH Inhibition in

  2026-07-08

  3-Deazaadenosine hydrochloride offers researchers a potent, selective tool to dissect methyltransferase-dependent pathways in hepatic stellate cell activation and liver fibrosis. Its high purity and robust solubility profile, backed by APExBIO’s quality assurance, enable reproducible results in advanced inflammation and proliferation studies.

• Macrophage M1 Polarization via TLR4 Inhibits CAC Progression

  2026-07-08

  Liu et al. demonstrate that Jiedu Xiaozheng Yin suppresses colitis-associated colorectal cancer in mice by promoting macrophage polarization toward the M1 phenotype through the TLR4 pathway. This study highlights immune modulation as a targeted strategy for CRC chemoprevention and provides mechanistic insight into tumor microenvironment control.

• Lyotropic Network Formation in Coil-Bottlebrush Diblocks via

  2026-07-07

  This study demonstrates that coil-bottlebrush diblock copolymers form robust three-dimensional network nanostructures in alkylimidazolium-based ionic liquids, largely independent of solvent alkyl chain length. These findings relax previous design constraints and provide new avenues for tailoring nanomaterial architectures with enhanced compositional flexibility.

• BAPTA Calcium Chelator: Precision Tools for Apoptosis Resear

  2026-07-07

  BAPTA stands out as a high-affinity calcium chelator, enabling researchers to dissect calcium-dependent apoptosis pathways with exceptional specificity. Explore how BAPTA empowers robust experimental workflows, delivers reproducible results in calcium signaling modulation, and provides practical troubleshooting strategies for challenging cell signaling studies.

• Sulfaphenazole as a CYP2C9 Inhibitor: Workflows and Solution

  2026-07-06

  Sulfaphenazole stands out as a selective CYP2C9 inhibitor, streamlining workflows in drug metabolism, vascular function, and infection research. Learn how to set up robust assays, optimize protocols, and troubleshoot challenges using APExBIO's validated compound.

• AmpliFold ‘Capture-and-Release’ Enhances LFA Sensitivity

  2026-07-06

  The referenced study introduces the AmpliFold ‘capture-and-release’ strategy, which leverages cleavable linkers and rebinding cycles to substantially increase the sensitivity of lateral flow assays (LFAs). This approach overcomes kinetic limitations of traditional LFAs and demonstrates up to a 16-fold improvement in detection limits, with implications for more robust point-of-care diagnostics.

• BRD4 Inhibition Enhances Erastin-Induced Ferroptosis via ROS

  2026-07-05

  The referenced study demonstrates that BRD4 inhibitors, including I-BET-762, markedly enhance erastin-induced ferroptosis across diverse cell lines by promoting ROS accumulation and downregulating FSP1. These mechanistic insights clarify how BET inhibition can synergize with ferroptosis inducers, with significant implications for cancer biology research and the development of combinatorial therapeutic strategies.

• Demethyleneberberine Inhibits NF-κB/MAPK in Autoimmune Hepat

  2026-07-04

  This study demonstrates that Demethyleneberberine (DMB), a natural isoquinoline alkaloid, significantly attenuates concanavalin A-induced autoimmune hepatitis in mice through targeted inhibition of NF-κB and MAPK signaling pathways. The findings highlight DMB’s mechanistic specificity and its translational relevance as an anti-inflammatory compound for preclinical liver disease research.

• AI-10-49: Precision CBFβ-SMMHC Inhibitor for AML Research

  2026-07-03

  AI-10-49 enables targeted, mechanism-based disruption of leukemogenic pathways in acute myeloid leukemia research by selectively antagonizing CBFβ-SMMHC. Its robust experimental performance and validated workflows empower both mechanistic studies and translational investigations, setting a new standard for selective leukemia inhibitor tools.

442 records 11/30 page Previous Next First page 上5页 1112131415 下5页 Last page